What happened
L&K Biomed reported consolidated results for FY2025: revenue of US$27M (+7.8% year on year), operating profit of US$459K (−78.5% year on year) and a net loss of US$11.7M (from a profit a year earlier).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$27M |
|---|---|
| Revenue vs a year earlier | +7.8% |
| Operating profit | US$459K |
| Net income | −US$11.7M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-19, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260219900883 → open original filing |
Source: DART. Information only, not investment advice.